-
02.06.2026 | Chembio receives $1.8 million CARB-X grant to develop a rapid diagnostic test for typhoid fever
Chembio Diagnostic Systems, Inc. (Chembio), a wholly owned subsidiary of Biosynex, a leader in point-of-care (POC) diagnostics, today announced that it has been awarded a $1.8 million grant from CARB-X to support the development of a rapid point-of-care diagnostic test for acute typhoid fever.
-
02.05.2026 | CARB-X funds development of rapid test for typhoid fever
CARB-X announced today that it’s awarding Chembio Diagnostic Systems $1.8 million to support the development of a rapid, finger stick–based diagnostic test for typhoid fever.
-
02.05.2026 | CARB-X to support development of typhoid fever diagnostic from Chembio
CARB-X is awarding US$1.8 million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi.
-
02.05.2026 | CARB-X awards $1.8M for Chembio Diagnostic Systems typhoid fever dx
CARB-X announced on Thursday that it has awarded $1.8 million to Biosynex subsidiary Chembio Diagnostic Systems to support the development of a rapid test for typhoid fever.
-
02.05.2026 | Visby Medical, Watchmaker Genomics partner to develop at-home respiratory pathogen detection tests
Visby Medical said on Thursday that it has inked a partnership with Watchmaker Genomicsto develop diagnostic tests for detecting respiratory pathogens in the at-home setting.
-
01.27.2026 | Clarametyx Biosciences strengthens scientific advisory board with expert appointments to advance pipeline programs
Drs. Bruce Forrest, George Siber, Obadiah Plante and David Zarley appointed to guide Clarametyx’s anti-biofilm technologies for chronic respiratory disease.
-
01.21.2026 | Replik: Ny satsning från Gates Foundation
Stefan Swartling Peterson, Otto Cars och medförfattare uppmanar Bill Gates att bidra i kampen mot antibiotikaresistens .
-
01.20.2026 | Topline results: Antibody therapy lowers inflammatory biomarkers in cystic fibrosis
In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and Pseudomonas aeruginosa burden vs. standard of care, according to phase 1b/2a trial topline results.
-
01.19.2026 | GARDP and Debiopharm partner to advance antibiotic for drug-resistant gonorrhea
The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.
-
01.09.2026 | Clarametyx Biosciences announces positive topline data from Phase 2a study evaluating CMTX-101 in cystic fibrosis
CMTX-101 treatment produced clinically meaningful reductions in key inflammatory biomarkers and pulmonary Pseudomonas aeruginosa burden, and preservation of pulmonary function.
-
01.08.2026 | Quest, Labcorp add fully at-home STI test to women’s health offerings
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health.
Toggle navigation